Kabra Drugs Statistics

Total Valuation

Kabra Drugs has a market cap or net worth of INR 289.47 million. The enterprise value is 80.85 million.

Market Cap	289.47M
Enterprise Value	80.85M

Important Dates

The last earnings date was Friday, May 30, 2025.

Earnings Date	May 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Kabra Drugs has 23.71 million shares outstanding. The number of shares has increased by 149.87% in one year.

Current Share Class	23.71M
Shares Outstanding	23.71M
Shares Change (YoY)	+149.87%
Shares Change (QoQ)	+85.02%
Owned by Insiders (%)	18.76%
Owned by Institutions (%)	0.24%
Float	19.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	1.17
P/TBV Ratio	1.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.45
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.70

Financial Position

The company has a current ratio of 43.84, with a Debt / Equity ratio of 0.02.

Current Ratio	43.84
Quick Ratio	38.16
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.09
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -8.44% and return on invested capital (ROIC) is -7.73%.

Return on Equity (ROE)	-8.44%
Return on Assets (ROA)	-7.24%
Return on Invested Capital (ROIC)	-7.73%
Return on Capital Employed (ROCE)	-7.00%
Revenue Per Employee	n/a
Profits Per Employee	-350,194
Employee Count	31
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Kabra Drugs has paid 5,000 in taxes.

Income Tax	5,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +54.36% in the last 52 weeks. The beta is -0.24, so Kabra Drugs's price volatility has been lower than the market average.

Beta (5Y)	-0.24
52-Week Price Change	+54.36%
50-Day Moving Average	9.83
200-Day Moving Average	6.03
Relative Strength Index (RSI)	99.53
Average Volume (20 Days)	30,219

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-17.25M
Pretax Income	-10.85M
Net Income	-10.86M
EBITDA	-17.18M
EBIT	-17.25M
Earnings Per Share (EPS)	-0.99

Full Income Statement

Balance Sheet

The company has 212.99 million in cash and 4.37 million in debt, giving a net cash position of 208.62 million or 8.80 per share.

Cash & Cash Equivalents	212.99M
Total Debt	4.37M
Net Cash	208.62M
Net Cash Per Share	8.80
Equity (Book Value)	246.55M
Book Value Per Share	13.15
Working Capital	245.88M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -47.07 million and capital expenditures -513,000, giving a free cash flow of -47.58 million.

Operating Cash Flow	-47.07M
Capital Expenditures	-513,000
Free Cash Flow	-47.58M
FCF Per Share	-2.01

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kabra Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-149.87%
Shareholder Yield	n/a
Earnings Yield	-3.75%
FCF Yield	-16.44%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1